Aclarion posts loss, addresses Nasdaq delisting notices

BROOMFIELD — Aclarion Inc. (Nasdaq: ACON), a Broomfield-based medical-device startup, recorded a loss of $1.18 million during the first quarter, compared with a loss of $773,000 during the same period a year ago.

Aclarion has recorded limited sales to date, with first-quarter revenue of $25,470, compared with $9,026 the prior year, according to a filing with the U.S. Securities and Exchange Commission.

Aclarion posted a net loss of $7.6 million in 2022, compared with a net loss of $4.95 million in 2021.

Aclarion is a health care technology company that uses biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location…